Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2023, representing a year-on-year increase of 25%[1]. - The company's operating revenue for the first half of 2023 was ¥121,558,474.72, a decrease of 54.23% compared to ¥265,566,868.41 in the same period last year[23]. - The net profit attributable to shareholders for the first half of 2023 was -¥9,873,625.74, representing a decline of 109.87% from ¥100,062,840.78 in the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥21,243,399.72, down 122.18% from ¥95,777,715.25 year-on-year[23]. - The net cash flow from operating activities was ¥1,710,492.47, a significant drop of 96.43% compared to ¥47,906,056.59 in the same period last year[23]. - The total profit for the period was ¥1,111,076.89, down 99.06% year-on-year, while the net profit attributable to the parent company was -¥9,873,625.74, a decrease of 109.87%[105]. Research and Development - Research and development expenses increased by 10% to RMB 50 million, focusing on innovative technologies in molecular testing[1]. - R&D expenses increased by 46.78% to ¥41,815,147.61 compared to ¥28,487,564.18 in the same period last year[88]. - R&D expenses accounted for 34.40% of operating revenue, an increase of 23.67 percentage points compared to 10.73% in the previous year[24]. - The number of R&D personnel increased by 38.41%, adding 53 new employees, including 43 with master's degrees and 6 with doctoral degrees[89]. - The R&D team is led by Dr. Wang Chunxiang, with 69.11% of the team holding a master's degree or higher, indicating a highly qualified workforce[98]. Product Development and Innovation - New product launches include a cutting-edge molecular diagnostic kit, projected to contribute an estimated RMB 100 million in revenue by year-end[1]. - The company has developed over 700 products and holds 58 domestic medical device registrations, with 37 products registered overseas[30]. - The company has established six technical platforms and 23 core technologies in molecular detection, along with 17 domestic invention patents and 40 utility model patents[30]. - The company has developed over 70 types of nucleic acid preservation reagents, with 16 products registered or filed as medical devices, making it one of the most comprehensive providers in China[34]. - The company has developed a molecular diagnostic kit for colorectal cancer risk assessment, with a revenue of 695 million, reflecting a 62.91% increase[94]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 30% market share in the region by 2025[1]. - The company is actively pursuing market expansion strategies, targeting regions such as the EU and Southeast Asia for its new product offerings[84]. - The company has achieved significant international presence with its nucleic acid detection kits registered in various countries including the EU and Brazil[83]. - The overseas sales revenue for the reporting period was ¥1,533,100, accounting for 1.26% of total sales, highlighting the potential for future growth in international markets[115]. Compliance and Governance - The board of directors has confirmed the authenticity and completeness of the financial report, with all members present at the meeting[1]. - The company has no significant non-operational fund occupation by controlling shareholders or related parties[1]. - There are no violations of decision-making procedures regarding external guarantees[1]. - The company has implemented a standardized SOP system and achieved ISO9001:2015 and ISO13485:2016 quality management system certifications to ensure product quality[109]. Shareholder and Stock Management - The company has committed to not transferring or entrusting the management of shares held before the public offering for 36 months after listing on the Shanghai Stock Exchange[148]. - The company will adhere to relevant laws and regulations when reducing its shareholdings, ensuring compliance with the Company Law and Securities Law[148]. - The company has established a commitment to maintain control arrangements to ensure stable operations after the lock-up period[148]. - The company will ensure that any share reduction complies with the regulations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange[148]. Financial Management - The company has allocated 240,000,000.00 RMB for working capital, with 113,682,262.02 RMB utilized, accounting for 47.37% of the total[1]. - The total amount used for share repurchase in a single accounting year shall not exceed 40% of the audited net profit attributable to the parent company from the previous year[160]. - The company has received CNY 92,379,000 in cash from testing service fees, with CNY 77,544,700 still outstanding[123]. - The company has a significant increase in trading financial assets, which rose by 106.59% to CNY 831,706,145.53 from CNY 402,593,063.19[129]. Environmental Responsibility - The company invested 1.6568 million yuan in environmental protection during the reporting period[140]. - The company has implemented measures to ensure compliance with environmental standards, including proper treatment of wastewater and solid waste[142].

(本页以下无正文) 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易 所科创板股票上市规则》及《江苏康为世纪生物科技股份有限公司章程》（以下 简称"《公司章程》"）等有关规定，我们作为江苏康为世纪生物科技股份有限公 司（以下简称"公司"）独立董事，本着对公司及全体股东负责的态度，基于独立、 客观、审慎的原则，现就公司第一届董事会第二十五次会议审议的相关事项发表 如下独立意见： 一、关于对《2023 年半年度募集资金存放与使用情况的专项报告》的独立 意见 公司编制的《2023 年半年度募集资金存放与使用情况的专项报告》符合《上 海证券交易所科创板股票上市规则》、《上海证券交易所科创板上市公司自律监管 指引第 1 号——规范运作》及《上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求》等相关法律法规、规章及《江苏康为世纪生物科技股 份有限公司募集资金管理制度》的规定。不存在改变或变相改变募集资金用途的 情形，不存在损害公司及股东利益的情形，不会对募投项目的实施造成不利影响。 募集资金具体使用情况与公司已披露情况一致，不存在变相改变募集资金用途和 损害股东利益的情况，不存在违 ...

证券代码：688426 证券简称：康为世纪 公告编号：2023-035 江苏康为世纪生物科技股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》和《上海证券交易所科创板股票上市规则》等相关规 定，江苏康为世纪生物科技股份有限公司（以下简称"公司"）就 2023年半年度募集资金 存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金的金额和资金到账时间 2022 年 9 月 1 日，经中国证券监督管理委员会《关于同意江苏康为世纪生物科技股 份有限公司首次公开发行股票注册的批复》（证监许可[2022]2003 号）核准，公司向社会 首次公开发行人民币普通股（A 股）股票 2,329.0278 万股，股票面值为人民币 1 元，发 行价格为每股人民币 48.98 元 ...

证券代码：688426 证券简称：康为世纪 公告编号：2023-037 江苏康为世纪生物科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●会议召开时间：2023 年 9 月 7 日（星期四）下午 13:00-15:00 ●会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com） ●会议召开方式：视频和线上文字互动 ●投资者可于 2023 年 9 月 5 日（星期二）中午 12:00 前登录上证路演中心网站 首页点击"提问预征集"栏目或通过公司邮箱 IRM@cwbio.cn 进行提问。公司将在本次业 绩说明会上对投资者普遍关注的、有代表性的问题逐条进行回答。 江苏康为世纪生物科技股份有限公司(下称"公司")已于 2023 年 8 月 30 日在上海 证券交易所网站（www.sse.com.cn）披露了《2023 年半年度报告》及其摘要，为了便 于广大投资者更全面、更深入地了解公司 2023 年半年度的经营成果、财务状况等信 息，公司参加了由上海 ...

一、审议通过《关于<2023 年半年度报告>及其摘要的议案》 董事会认为：公司《2023 年半年度报告》及其摘要的编制和审议程序符合相关法律 法规及《公司章程》等内部规章制度的规定，内容与格式符合《公开发行证券的公司信 息披露内容与格式准则第 3 号—半年度报告的内容与格式（2021 年修订）》等有关文件 的要求，真实、准确、完整地反映了公司 2023 年半年度财务状况和经营成果等事项， 不存在任何虚假记载、误导性陈述或重大遗漏。 表决结果：同意 9 票、反对 0 票、弃权 0 票 具体内容详见公司同日披露于上海证券交易所网站（www.see.com.cn）的《2023 年 半年度报告》以及《2023 年半年度报告摘要》（公告编号：2023-034）。 证券代码：688426 证券简称：康为世纪 公告编号：2023-033 江苏康为世纪生物科技股份有限公司 第一届董事会第二十五次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏康为世纪生物科技股份有限公司(下称"公司")第一届董事会第二十五次会议于 2023 ...

证券代码：688426 证券简称：康为世纪 公告编号：2023-036 二、审议通过《关于<2023 年半年度募集资金存放与使用情况的专项报告>的议案》 监事会认为：公司 2023 年半年度募集资金存放与使用情况符合有关上市公司募集 资金存放与使用的相关法律法规，以及《公司章程》、《公司募集资金管理制度》等内部 规定，对募集资金进行了专户存储和专项使用，及时履行了相关信息披露义务，募集资 金具体使用情况与公司披露情况一致，不存在变相改变募集资金用途和损害股东利益的 江苏康为世纪生物科技股份有限公司 第一届监事会第十二次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏康为世纪生物科技股份有限公司(下称"公司")第一届监事会第十二次会议于 2023 年 8 月 28 日上午 11 点以现场结合通讯形式召开,本次会议通知及相关材料已于 2023 年 8 月 18 日发出。会议应出席监事 3 人,实际到会监事 3 人，本次会议由监事会主 席陈胜兰主持。 本次会议的召集、召开符合《中华人民共和国公司法》等法律法规以及 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥76,943,090.83, representing a decrease of 37.35% compared to the same period last year[3] - The net profit attributable to shareholders was ¥3,989,440.66, down 89.74% year-on-year[3] - The net cash flow from operating activities was -¥9,225,991.59, a decline of 127.19% compared to the previous year[3] - Total operating revenue for Q1 2023 was ¥76,943,090.83, a decrease of 37.4% compared to ¥122,814,896.09 in Q1 2022[17] - Net profit for Q1 2023 was ¥9,503,471.21, a decline of 75.5% from ¥38,880,499.79 in Q1 2022[18] - The company reported a comprehensive income total of ¥9,182,584.27 for Q1 2023, down from ¥38,865,774.28 in Q1 2022[18] - The company experienced a significant decrease in sales revenue, indicating potential challenges in market demand or competition[17] Research and Development - Research and development expenses totaled ¥19,039,632.01, which is an increase of 38.86% year-on-year[3] - The proportion of R&D expenses to operating revenue was 24.75%, an increase of 13.58 percentage points compared to the previous year[4] - Research and development expenses for Q1 2023 were ¥19,039,632.01, an increase of 38.8% from ¥13,711,047.94 in Q1 2022[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,940,172,963.71, a decrease of 0.51% from the end of the previous year[4] - As of March 31, 2023, the total current assets amounted to RMB 1,569,355,696.88, a decrease from RMB 1,626,664,083.19 as of December 31, 2022, reflecting a decline of approximately 3.5%[12] - The total liabilities decreased to RMB 1,569,355,696.88 from RMB 1,626,664,083.19, indicating a decline of approximately 3.5%[13] - Total liabilities as of Q1 2023 were ¥125,659,684.49, compared to ¥158,416,801.31 in the previous period[14] - The total non-current assets increased to RMB 370,817,266.83 from RMB 323,413,601.32, reflecting an increase of approximately 14.7%[13] Cash Flow - The cash and cash equivalents were reported at RMB 410,812,747.09, down from RMB 1,031,534,445.52, indicating a significant decrease of about 60.3%[12] - Cash inflow from operating activities in Q1 2023 was ¥66,528,597.93, down 48.0% from ¥128,091,616.53 in Q1 2022[19] - The net cash flow from operating activities was -$9,225,991.59, a significant decrease compared to $33,933,089.12 in the previous year, indicating a decline in operational performance[21] - The company reported a total cash outflow of $620,722,341.81 for the quarter, contrasting with a cash inflow of $134,161,295.71 in the same quarter last year[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,413[8] - The largest shareholder, Beijing Kangwei Century Biotechnology Co., Ltd., holds 42,000,000 shares, accounting for 44.91% of the total shares[8] - Total equity attributable to shareholders was ¥1,791,684,776.75, an increase from ¥1,780,346,411.28 in the previous period[14] Operational Challenges - The company experienced a significant decline in main business income due to changes in market demand[6] - The company has not disclosed any new product developments or market expansion strategies in the current report[12] Costs and Expenses - Total operating costs for Q1 2023 were ¥68,061,840.64, down 10.5% from ¥76,035,786.15 in Q1 2022[17] - The company paid $34,649,016.72 in employee compensation, up from $29,007,526.33, indicating increased labor costs[21] - Tax payments increased to $13,454,499.18 from $10,759,338.00, reflecting higher tax obligations[21] Investment Activities - Cash inflow from investment activities totaled $542,802,500.88, up from $234,976,184.10 year-over-year, reflecting increased investment recovery[21] - The cash outflow from investment activities was $1,158,990,407.49, compared to $132,533,414.96 in the previous year, resulting in a net cash flow from investment activities of -$616,187,906.61[21] Accounting Standards - The company is implementing new accounting standards starting in 2023, which may affect future financial reporting[22]

Financial Performance - In 2022, the company achieved a net profit attributable to shareholders of RMB 159,258,880.74, with a distributable profit of RMB 172,983,356.83 by the end of the year[5]. - The proposed profit distribution plan includes a cash dividend of RMB 5.20 per 10 shares, totaling RMB 48,631,945.96, which accounts for 30.54% of the net profit[5]. - The company has not yet achieved profitability since its listing[6]. - The company reported a total revenue of RMB 1.5 billion for the fiscal year 2022, representing a year-over-year growth of 20%[14]. - The company's operating revenue for 2022 was CNY 521.6 million, representing a year-on-year increase of 54.11% compared to CNY 338.5 million in 2021[24]. - The net profit attributable to shareholders for 2022 was CNY 159.3 million, a 26.55% increase from CNY 125.8 million in 2021[24]. - The basic earnings per share for 2022 was CNY 2.16, a 20.00% increase from CNY 1.80 in 2021[25]. - The total assets at the end of 2022 reached CNY 1.95 billion, a 200.58% increase from CNY 648.8 million at the end of 2021[24]. - The net assets attributable to shareholders increased by 224.72% to CNY 1.78 billion at the end of 2022, compared to CNY 548.3 million at the end of 2021[24]. - The company reported a net cash flow from operating activities of CNY 107.4 million for 2022[24]. Research and Development - Research and development investments increased by 40%, focusing on next-generation sequencing technologies[15]. - Research and development expenses for 2022 totaled 74.02 million yuan, an increase of 91.83% compared to the previous year[38]. - The R&D team expanded to 185 members, a 40.15% increase from the previous year, with 71.35% holding master's degrees or higher[39]. - The company has developed 122 types of molecular detection raw enzymes, including Taq polymerase and high-fidelity PCR enzymes, with performance levels meeting or exceeding imported products[45]. - The company has established a comprehensive fluorescence quantitative molecular platform and a second-generation sequencing reagent R&D system for its nucleic acid detection kits[198]. Product Development and Innovation - The company plans to introduce a new point-of-care testing (POCT) product line in Q2 2023, aiming for a 15% contribution to total revenue[15]. - The company has launched several molecular diagnostic kits, including the first Class III registration certificate for Helicobacter pylori nucleic acid detection based on fecal samples, filling a gap in the industry[52]. - The company has developed a non-invasive prenatal trace gene testing kit, achieving a product launch with a market demand of 450 million[116]. - The company is focusing on the development of specific detection reagents and dedicated instruments to improve diagnostic effectiveness[83]. - The company has developed a series of alternative reagents for nucleic acid mass spectrometry, which are more cost-effective than imported products and reduce operational steps and detection time[97]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[16]. - The company is actively pursuing market expansion through the introduction of new diagnostic kits, such as the Monkeypox Virus Nucleic Acid Detection Kit, registered in June 2022[106]. - The company is collaborating with international giants and research institutions to leverage resources and expand its global market presence in molecular detection[83]. - The company is strategically positioned for future growth, leveraging its intellectual property and expanding its market presence both domestically and internationally[99]. Risk Management - The company has disclosed potential risk factors that may adversely affect its operations in the management discussion section[4]. - The company faces risks related to the slow progress and high costs of new product development, which may lead to potential failures in obtaining necessary registrations[129]. - The company is at risk of losing core technical personnel due to intense competition for talent in the molecular detection field[129]. - The company’s core technology and proprietary techniques are at risk of leakage if not effectively managed, which could adversely affect operations[129]. Compliance and Quality Assurance - The audit report issued by the accounting firm was a standard unqualified opinion[6]. - The company has ensured the accuracy and completeness of the annual report, with all board members present at the meeting[6]. - The company follows ISO9001:2015 and ISO13485:2016 quality management systems in its R&D processes, ensuring compliance and quality assurance[57]. Sales and Distribution - The company utilizes a "direct sales primarily, with distributors as a supplement" sales model, ensuring high cash return rates from direct sales to research institutions and medical testing labs[61]. - The company has established a sales network with five domestic sales regions and one international sales region, including marketing offices in ten cities such as Beijing, Shanghai, and Guangzhou[61]. - The company achieved overseas sales revenue of 33.45 million yuan, accounting for 6.41% of total sales during the reporting period[130]. Financial Position and Assets - Cash and cash equivalents at the end of the period reached ¥1,031,534,445.52, accounting for 52.90% of total assets, a significant increase of 707.03% compared to the previous period[163]. - The total procurement amount from the top five suppliers was 34.57 million, representing 17.62% of the annual total procurement, with no purchases from related parties[157]. - The company reported a significant increase in accounts payable to ¥44,070,076.95, which is 2.26% of total liabilities, reflecting a 148.21% increase driven by larger procurement volumes[165].

证券代码：688426 证券简称：康为世纪 公告编号：2023-011 江苏康为世纪生物科技股份有限公司 关于参加 2022 年度生物制品专场集体业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●会议召开时间：2023 年 4 月 26 日（星期三）下午 15:00-16:00 ●会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com） ●会议召开方式：视频与网络文字互动 ●投资者可于 2023 年 4 月 26 日（星期三）中午 12:00 前登录上证路演中心网站 首页点击"提问预征集"栏目或通过公司邮箱 kangweishiji@cwbio.cn 进行提问。公司将 在本次业绩说明会上对投资者普遍关注的、有代表性的问题逐条进行回答。 江苏康为世纪生物科技股份有限公司(下称"公司")已于 2023 年 2 月 28 日在上海 证券交易所网站（www.sse.com.cn）披露了《2022 年度业绩快报公告》（公告编号： 2023-009）, ...